Moderna and the EU formally agreed in November 2020 to supply 160 million doses of Moderna's mRNA-based COVID-19 vaccine, bringing the bloc's overall supply to more than 2 billion doses. Because Moderna's vaccine must be administered in a two-dose regimen, this order could inoculate 80 million patients. This supply deal occurred almost a week after the EU accepted Moderna's vaccine, mRNA-1273, for rolling review based on phase 3 study results showing 95% efficacy.
Vaccine pricing for mRNA-1273 has not yet been announced. According to Reuters, the EU is hoping to pay $25 per vaccine dose, meanwhile Moderna CEO Stéphane Bancel is seeking a rate between $27 and $35 per dose.
Moderna has contracted with Sweden's Recipharm to handle fill-finish duties for mRNA-1273 at its manufacturing plant in Monts, France. Recipharm has, in turn, made investments in increased staff to grow its manufacturing capabilities.
Source:asamonitor.pub/33ffwzG
The U.S. Department of Health...
